Assembly Biosciences (NASDAQ:ASMB) Stock Price Passes Above Two Hundred Day Moving Average – What’s Next?

Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $28.32 and traded as high as $29.95. Assembly Biosciences shares last traded at $28.97, with a volume of 177,777 shares traded.

Wall Street Analyst Weigh In

Several research firms recently commented on ASMB. Guggenheim reaffirmed a “buy” rating and issued a $43.00 price objective on shares of Assembly Biosciences in a research report on Thursday, May 28th. Wall Street Zen cut Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Monday, April 20th. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Assembly Biosciences in a research note on Monday, May 4th. Finally, Mizuho set a $45.00 price target on Assembly Biosciences and gave the stock an “outperform” rating in a research report on Monday, June 15th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $44.00.

Assembly Biosciences Trading Up 0.2%

The firm’s 50 day simple moving average is $26.70 and its 200-day simple moving average is $28.32. The stock has a market capitalization of $460.33 million, a price-to-earnings ratio of -263.34 and a beta of 1.08.

Assembly Biosciences (NASDAQ:ASMB) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.11. The company had revenue of $8.21 million during the quarter, compared to the consensus estimate of $9.27 million. Assembly Biosciences had a negative net margin of 8.98% and a negative return on equity of 4.21%. As a group, equities research analysts predict that Assembly Biosciences, Inc. will post 1.9 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE raised its stake in shares of Assembly Biosciences by 6,382.7% during the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 3,319 shares in the last quarter. Seven Fleet Capital Management LP bought a new position in shares of Assembly Biosciences in the fourth quarter valued at $147,000. Acadian Asset Management LLC increased its holdings in Assembly Biosciences by 42.1% during the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 6,823 shares during the last quarter. Charles Schwab Investment Management Inc. acquired a new position in Assembly Biosciences during the fourth quarter worth $228,000. Finally, Virtus Investment Advisers LLC bought a new stake in Assembly Biosciences during the fourth quarter worth $251,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.